Evidence map›Paper›PMID 28892001›Full record

ArticleAntibiotics (Basel, Switzerland)2017

Synthesis and Immunological Evaluation of Virus-Like Particle-Milbemycin A₃/A₄ Conjugates.

Andris Zeltins, Māris Turks, Dace Skrastina, Jevgeņija Lugiņina, Ieva Kalnciema, Ina Balke, Ērika Bizdēna, Vitalijs Skrivelis

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Andris ZeltinsLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia. anze@biomed.lu.lv.
Māris TurksInstitute of Technology of Organic Chemistry, Riga Technical University, P. Valdena Str. 3, LV-1048 Riga, Latvia. maris.turks@rtu.lv.
Dace SkrastinaLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia. daceskr@biomed.lu.lv.
Jevgeņija LugiņinaInstitute of Technology of Organic Chemistry, Riga Technical University, P. Valdena Str. 3, LV-1048 Riga, Latvia. ieva.kalnciema@biomed.lu.lv.
Ieva KalnciemaLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia. inab@biomed.lu.lv.
Ina BalkeLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.
Ērika BizdēnaInstitute of Technology of Organic Chemistry, Riga Technical University, P. Valdena Str. 3, LV-1048 Riga, Latvia. jevgenija.luginina@rtu.lv.
Vitalijs SkrivelisPharmIdea Ltd., Rupnicu 4, Olaine, Riga District, LV-2114 Olaine, Latvia. pharmidea@pharmidea.lv.
Latvian Biomedical Research and Study Centre · LVRiga Technical University · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Milbemycins are macrolide antibiotics with a broad spectrum of nematocidal, insecticidal, and acaricidal activity. To obtain milbemycin A₃/A₄ derivatives suitable for chemical conjugation to protein carriers (milbemycin haptens), succinate linker and a novel 17-atom-long linker containing a terminal carboxylic acid group were attached to the milbemycin core in a protecting group-free synthesis. The obtained milbemycin A₃/A₄ derivatives were coupled to Potato virus Y-like nanoparticles by the activated ester method. The reaction products were characterized and used in mice immunization experiments. It was found that the mice developed weak specific immune responses toward all tested milbemycin haptens.

Indexed as

ELISAhydrophobic haptenmacrocyclic lactoneplant virus

Identifiers

PMID28892001
PMCPMC5617982
OpenAlexW2755081516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.